Lymphoma. Hodgkinlymfomen and non-Hodgkin's disease
Information on current developments in both regular and alternative or complementary treatments and resources for lymphoma - non-Hodgkin's lymphoma and Hodgkin's disease at all stages.
Recent articles in left column more or less in alphabetical order classified
Experiences of cancer patients with complementary approaches can be found by experience stories on our website and there are also some videos of experiences of cancer patients with complementary approaches to see. To click on video button top left of this page. Or visit the website of the SNFK information where movies are shown on complementary approaches to cancer.
Brentuximab Vedotin (SGN-35) shows successful approach for advanced and recurrent lymphoma, non-Hodgkin lymphoma with positive CD30 expression. According to the Volkskrant has caused a run on this drug, creating a shortage. Article posted June 7, 2011
Brentuximab Vedotin (SGN-35) appears as a successful approach of non-Hodgkin lymphoma that is emerging is a shortage of this drug. So reports the Times today in a full page article. I have to study it even overtook those recently published in the NEJM (New England Journal of Medicine) and the results look very promising indeed. But it is only a phase I / II studies and is rather premature to present this as pontifical ljikt me. On the website of Seattle Genetics is more about ongoing studies with this drug.
Here is the abstract of the study. If you want to read the full study report click here, it's free to read .
Brentuximab Vedotin (SGN-35) for Relapsed CD30-positive lymphomas
N Engl J Med 2010, 363:1812-1821 November 4, 2010
Background
Hodgkin's lymphoma and anaplastic large cell lymphoma are the two musts common tumors expressing CD30. Previous Attempts to target the CD30 antigen with monoclonal-based therapies have Shown minimal activity. To Enhance the antitumor activity of CD30-directed therapy, the antitubulin agent monomethyl auris tatin E (MMAE) was attached to a CD30-specific monoclonal antibody by an enzyme-cleavable linker, Producing the antibody-drug conjugate brentuximab vedotin (SGN-35).
Methods
In this phase 1, open-label, multicenter dose-escalation study, we Administered brentuximab vedotin (at a dose of 0.1 to 3.6 mg per kilogram of body weight) every 3 weeks to 45 patients with relapsed or refractory CD30-positive hematologic cancers, Primarily Hodgkin's lymphoma and anaplastic large cell lymphoma. Received Patients had a median of three previous chemotherapy regimens (range, one to seven), and 73% had under-gone voice autologous cell transplantation.
Results
The maximum tolerated dose was 1.8 mg per kilogram, Administered Every 3 weeks. Objective responses, include 11 complete remission, Were observed in 17 patients. Of 12 patients who Received the 1.8-mg-per-kilogram dose, six (50%) had an objective response. The median duration of response was 9.7 months at least. Tumor regression was observed in 36 of 42 patients who Could Be Evaluated (86%). The Most common adverse events Were fatigue, pyrexia, diarrhea, nausea, neutropenia, and peripheral neuropathy.
Conclusions
Brentuximab vedotin objectifying induced durable responses and resulted in tumor regression for relapsed or refractory must patiënten with CD30-positive lymphomas in this phase 1 study. Primarily Treatment was associated with grade 1 or 2 (mild-to-moderate) toxic effects. (Funded by Seattle Genetics, ClinicalTrials.gov number, NCT00430846.)
References
1
Diehl V, Franklin J, Pfreundschuh M, et al Standard and Increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003, 348:2386-2395 [Erratum, N Engl J Med 2005; 353 : 744.]
Full Text | Web of Science | Medline2
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249
CrossRef | Web of Science | Medline3
Sureda A, Constans M, Iriondo A, et al Prognostic factors affects long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 2005, 16:625-633
CrossRef | Web of Science | Medline4
Majhail NS, Weisdorf DJ, TE Defoor, et al Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006, 12:1065-1072
CrossRef | Web of Science | Medline5
Martinez C, Canals C, Alessandrino E, et al Relapse of Hodgkin's lymphoma (HL) after autologous stem cell transplantation (ASCT): Prognostic factors in 462 patients registered in the database of the EBMT. J Clin Oncol 2010, 28: Suppl: 7s-7s
CrossRef6
Younes A. Novel Treatment Strategies for Patients with relapsed classical Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2009:507-19.
7
Stein H, Delsol G, Pileri SA, Weiss LM, Poppema S, Jaffe ES. Classical Hodgkin lymphoma: introduction. In Swerdlow SH, Campo E, Harris NL, et al, eds. WHO classification of haematopoietic and lymphoid tissues or tumoren. Lyon, France: International Agency for Research on Cancer, 2008:326-29.
8
van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells: a Possible Explanation for the Characteristic T-cell infiltrates in Hodgkin's lymphoma. Am J Pathol 1999, 154:1685-1691
CrossRef | Web of Science | Medline9
Re D, Thomas RK, Behringer K, Diehl V. From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood 2005, 105:4553-4560
CrossRef | Web of Science | Medline10
Dürkop H Latza U, Hummel M, Eitelbach F, Seed B, Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family That is Characteristic for Hodgkin's disease. Cell 1992, 68:421-427
CrossRef | Web of Science | Medline11
Falini B, Pileri S, Pizzolo G, et al CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood 1995, 85:1-14
Web of Science | Medline12
Matsumoto K, Terakawa M, Miura K, Fukuda S, Nakajima T, Saito H. Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J Immunol 2004, 172:2186-2193
Web of Science | Medline13
Tian ZG, Longo DL, Funakoshi S, et al In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large cell lymphoma xenografts. Cancer Res 1995, 55:5335-5341
Web of Science | Medline14
Ansell SM, Horwitz SM, Engert A, et al Phase I / II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large cell lymphoma. J Clin Oncol 2007, 25:2764-2769
CrossRef | Web of Science | Medline15
Forero-Torres A, Leonard JP, Younes A, et al A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin's lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009, 146:171-179
CrossRef | Web of Science | Medline16
Doro Nina SO, Toki BE, Torgov MY, et al Development of potent monoclonal antibody conjugates for cancer therapy auris tatin. Nat Biotechnol 2003, 21:778-784
CrossRef | Web of Science | Medline17
Hamblett KJ, Senter PD, Chace DF, et al Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res 2004, 10:7063-7070
CrossRef | Web of Science | Medline18
Sun MM, Beam KS, Cerveny CG, et al Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 2005, 16:1282-1290
CrossRef | Web of Science | Medline19
McDonagh CF, Turcott E, Westendorf L, et al Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment. Protein Eng Des Sel 2006, 19:299-307
CrossRef | Web of Science | Medline20
Oflazoglu E, Kissler KM, Sievers EL, Grewal IS, Gerber HP. Combination of the anti-CD30-tatin auris-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol 2008, 142:69-73
CrossRef | Web of Science | Medline21
Weihrauch MR, Manzke O, Beyer M, et al Elevated serum levels of CC thymus and activation-related chemokine (TARC) in Primary Hodgkin's disease: Potential for a Prognostic Factor. Cancer Res 2005, 65:5516-5519
CrossRef | Web of Science | Medline22
Niens M, Visser L, Nolte IM, et al Serum chemokine levels in Hodgkin lymphoma patient: Highly Increased levels of CCL17 and CCL22. Br J Haematol 2008, 140:527-536
CrossRef | Web of Science | Medline23
Oken MM, Creech RH, Tormey DC, et al Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982, 5:649-655
CrossRef | Web of Science | Medline24
Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Bethesda, MD: Cancer Therapy Evaluation Program, 2006. ( http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf .)
25
Cheson BD, Pfistner B Juweid ME, et al Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586
CrossRef | Web of Science | Medline26
Little R, Wittes RE, Longo DL, Wilson WH. Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant. J Clin Oncol 1998, 16:584-588
Web of Science | Medline27
Rule S, Tighe M, Davies S, Johnson S. Vinorelbine in the treatment of lymphoma. Hematol Oncol 1998, 16:101-105
CrossRef | Web of Science | Medline28
Zinzani PL, Bendandi M Stefoni V, et al Value of gemcitabine treatment in Heavily pretreated Hodgkin's disease patient. Haematologica 2000, 85:926-929
Medline29
Venkatesh H, Di Bella N, Flynn TP, Vellek MJ, Boehm KA, Asmar L. Results of a multicenter phase II trial of single agent gemcitabine in patient with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma 2004, 5:110-115
CrossRef | Medline30
Aurer I, Radman I, Nemet D, et al Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease. Onkologie 2005, 28:567-571
CrossRef | Web of Science | Medline31
Oki Y, Pro B, Fayad LE, et al Phase 2 study of gemcitabine in combination with rituximab in patient with recurrent or refractory Hodgkin lymphoma. Cancer 2008, 112:831-836
CrossRef | Web of Science | Medline32
Bartlett NL, Niedzwiecki D, Johnson JL, et al Gemcitabine, vinorelbine, and PEGylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007, 18:1071-1079
CrossRef | Web of Science | Medline33
Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 2006, 24:1633-1642
CrossRef | Web of Science | Medline34
Swain SM, Arezzo JC. Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management. Clin Adv Hematol Oncol 2008, 6:455-467
Medline
